IL10 and metastatic neoplasm: Immunization at day 7 with C57BL/6 PBMCs resulted in a decrease in Tregs to 10.0 ± 2.9% and 14 ± 3.2 in spleen and metastatic tumour, respectively (Figure 6A,B) and a decrease serum IL-10/IL-2 ratio (Figure 6C,D).